讨论
Mr罗小财2023-12-27 18:42
每日一选2023-12-27(美股)
注:排名不分先后$Reviva(RVPH)$ $奥德赛海洋探索(OMEX)$ $C4 Therapeutics(CCCC)$
简介:Reviva Pharmaceuticals Holdings, Inc.于2018年3月20日在英属维尔京群岛注册成立。Reviva是一家临床阶段制药公司,致力于解决中枢神经系统、心血管、代谢和炎症疾病领域未满足的医疗需求。Reviva的主要重点是开发其领先候选产品RP5063 (brilaroxazine),用于精神分裂症、双向情感障碍和重度抑郁症的治疗。Reviva还打算开发用于治疗PAH和IPF的RP5063。RP5063是一种血清素、多巴胺和烟碱受体活性化合物,目前正在临床开发中。
今开:3.78 | 昨收:3.9 |
最高:3.92 | 最低:3.4401 |
涨停价: | 跌停价: |
总市值:105532157 |
Mr罗小财2023-12-27 18:42
每日一选2023-12-27(美股)
注:排名不分先后$Reviva(RVPH)$ $奥德赛海洋探索(OMEX)$ $C4 Therapeutics(CCCC)$
产业链观察2023-10-31 06:43
#药闻简讯# 2023 年 10 月 30 日,Reviva Pharmaceuticals Holdings Inc.公司对成人精神分裂症患者进行的布利拉嗪关键性III期研究达到了主要终点和两个关键次要终点,这是继2021年II期研究获得积极数据之后的又一重大突破。这种血清素-多巴胺信号调节剂是该公司的主要候选药物,每天治疗一次。研究...
SeekingBiotech2023-08-18 00:55
$Reviva(RVPH)$ CNS Candidate
RVPH Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia.
Topline data in October
Reviva(RVPH)02-17 05:35
$Reviva(RVPH)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001437749-24-004592 Act: 34 Size: 38 KB 网页链接
Reviva(RVPH)02-14 06:05
$Reviva(RVPH)$ 424B4 Prospectus [Rule 424(b)(4)] Accession Number: 0001437749-24-003937 Act: 33 Size: 329 KB 网页链接
Reviva(RVPH)02-15 04:55
$Reviva(RVPH)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001172661-24-001403 Act: 34 Size: 90 KB 网页链接
Reviva(RVPH)02-14 19:05
$Reviva(RVPH)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-000430 Act: 33 Size: 1 KB 网页链接
Reviva(RVPH)02-15 05:05
$Reviva(RVPH)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001214659-24-002877 Act: 34 Size: 79 KB 网页链接
Reviva(RVPH)02-03 05:45
$Reviva(RVPH)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001437749-24-002961 Act: 33 Size: 1 MB 网页链接
浪荡美股2022-08-30 00:37
SeekingBiotech2023-08-18 00:55
$Reviva(RVPH)$ CNS Candidate
RVPH Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia.
Topline data in October查看全文
浪荡美股2022-08-30 00:37
蹊之美股生物医药2021-07-27 21:11
作者:林出
微信公众号:蹊之美股生物医药 / CaesarBiotech
Gainers:
Tyme Technologies (NASDAQ:TYME) +27%
IMV (NASDAQ:IMV) +25%Xenetic Biosciences (NASDAQ:XBIO)+20%Translate Bio (NASDAQ:TBIO) +14%Reviva Pharmaceuticals (NASDAQ:RVPH) +7%
Losers:...查看全文
明天周六2021-05-28 03:48
明天周六2021-05-12 03:39
$Reviva(RVPH)$ 买点看看查看全文
蹊之美股生物医药2021-04-27 20:40
作者:Dr. Sun
微信公众号:蹊之美股生物医药 / CaesarBiotech
标的公司:RVPH
1、234例急性精神分裂症或精神分裂症患者的临床试验达到安全性和有效性的终点
2、达到精神分裂症阳性和阴性综合征量表(PANSS)总分降低的主要终点
3、积极症状和消极症状均得到缓解
4...查看全文
$Reviva(RVPH)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001437749-24-004592 Act: 34 Size: 38 KB 网页链接
$Reviva(RVPH)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001214659-24-002877 Act: 34 Size: 79 KB 网页链接
$Reviva(RVPH)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001172661-24-001403 Act: 34 Size: 90 KB 网页链接
$Reviva(RVPH)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-000430 Act: 33 Size: 1 KB 网页链接
$Reviva(RVPH)$ 424B4 Prospectus [Rule 424(b)(4)] Accession Number: 0001437749-24-003937 Act: 33 Size: 329 KB 网页链接
$Reviva(RVPH)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001437749-24-002961 Act: 33 Size: 1 MB 网页链接
$Reviva(RVPH)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001493152-23-043240 Act: 34 Size: 186 KB 网页链接
$Reviva(RVPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001493152-23-042540 Size: 13 KB 网页链接
$Reviva(RVPH)$ 8-K Current report, items 1.01 and 9.01 Accession Number: 0001437749-23-032463 Act: 34 Size: 770 KB 网页链接
$Reviva(RVPH)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001437749-23-032462 Act: 33 Size: 560 KB 网页链接